Deolekar Pradnya, Vivek Kavita, Ghosh Souvik, Naseem Azra, Srivathsan Mayakalyani, Rai Vivek S, Signapurkar Sonal, Yadav Pramila
Pharmacology, D. Y. Patil Deemed to be University, Navi Mumbai, IND.
Critical Care, D. Y. Patil Hospital, Navi Mumbai, IND.
Cureus. 2023 Mar 14;15(3):e36112. doi: 10.7759/cureus.36112. eCollection 2023 Mar.
Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usually lasts for a longer period. PPIs are usually combined with antiemetics and prokinetic drugs. The price of PPIs for the same combination varies a lot, which can lead to a lot of financial burden on the patients. Objective To evaluate the cost ratio and percentage cost variation of commonly used PPIs in various combinations. Methodology The cost of different brands of commonly used PPIs in combination with other drugs was analyzed in our study. A total of 21 different combinations (10 capsules/tablets for oral use) were tabulated by referring to the "Monthly Index of Medical Specialities" October-December 2021, and 1mg online pharmacy. The cost ratio and percentage cost variation for various brands of a particular strength and dosage form were calculated and compared. Cost ratio > 2 and cost variation > 100% were considered significant. Results The results show a huge variation (1788.88%) in costs of different brands with the highest being rabeprazole 20 mg and domperidone 10 mg (cost ratio: 18.88, percentage cost variation: 1788.88%) in oral formulation, followed by pantoprazole 40 mg and itopride 150 mg. The minimum cost ratio (1.35) and percentage cost variation (1.35%) is for pantoprazole 40 mg and levosulpiride 75 mg. Logistic regression analysis between the number of brands and percentage cost variation gives an R value of 0.0923. Conclusion There is a wide variation in the prices of PPIs available in the market, which can inadvertently increase the financial burden of therapy on patients. Physicians need to be made aware of these price differences so that they can choose the best available alternative for patients, which can help in increasing compliance with the prescribed drugs.
引言 全球质子泵抑制剂（PPI）市场在2020年的估值为29亿美元，预计在预测期（2020 - 2027年）内将呈现4.30%的复合年增长率，因为它们经常被用于多种胃肠道疾病的治疗，且治疗通常持续较长时间。PPI通常与止吐药和促动力药物联合使用。相同组合的PPI价格差异很大，这可能给患者带来很大的经济负担。目的 评估常用PPI在各种组合中的成本比率和成本变化百分比。方法 在我们的研究中分析了不同品牌常用PPI与其他药物联合使用的成本。通过参考《2021年10月至12月医学专科月度索引》和1mg在线药房，列出了总共21种不同的组合（10种口服胶囊/片剂）。计算并比较了特定强度和剂型的不同品牌的成本比率和成本变化百分比。成本比率>2且成本变化>100%被认为具有显著性。结果 结果显示不同品牌的成本存在巨大差异（1788.88%），口服制剂中最高的是雷贝拉唑20mg和多潘立酮10mg（成本比率：18.88，成本变化百分比：1788.88%），其次是泮托拉唑40mg和伊托必利150mg。成本比率最低（1.35）和成本变化百分比最低（1.35%）的是泮托拉唑40mg和左舒必利75mg。品牌数量与成本变化百分比之间的逻辑回归分析得出R值为0.0923。结论 市场上PPI的价格存在很大差异，这可能无意中增加患者的治疗经济负担。需要让医生了解这些价格差异，以便他们能够为患者选择最佳的可用替代方案，这有助于提高患者对处方药的依从性。
